• Pharming cut full-year 2026 revenue guidance to US$375-395 million, lowered by US$30 million.
• Operating expense forecast tightened to US$315-320 million, improved by US$15 million.
• Outlook assumes significant Joenja growth, RUCONEST revenue stabilization, return to growth in the second half.
• Q2 revenue totaled US$90.2 million, down 3% year-on-year; Joenja rose 40% to US$17.9 million; RUCONEST fell 10% to US$72.3 million.
• Cash and marketable securities stood at US$159.5 million at quarter-end, down US$12.3 million from Q1 due to working-capital movements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.